Frost & Sullivan Independent Equity Research

Cellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged.


Company: Cellect        

Sector: Biotechnology

Report type: Q2-2018 Update Report

Published on: 20 August, 2018

Cellect research articles:

Close Menu
Font Resize